SG194235A1 - Methods of predicting the development of complement-mediated disease - Google Patents
Methods of predicting the development of complement-mediated disease Download PDFInfo
- Publication number
- SG194235A1 SG194235A1 SG2013080502A SG2013080502A SG194235A1 SG 194235 A1 SG194235 A1 SG 194235A1 SG 2013080502 A SG2013080502 A SG 2013080502A SG 2013080502 A SG2013080502 A SG 2013080502A SG 194235 A1 SG194235 A1 SG 194235A1
- Authority
- SG
- Singapore
- Prior art keywords
- complement
- methods
- predicting
- development
- mediated disease
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480929P | 2011-04-29 | 2011-04-29 | |
| PCT/US2012/035467 WO2012149329A2 (en) | 2011-04-29 | 2012-04-27 | Methods of predicting the development of complement-mediated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG194235A1 true SG194235A1 (en) | 2013-12-30 |
Family
ID=47073084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013080502A SG194235A1 (en) | 2011-04-29 | 2012-04-27 | Methods of predicting the development of complement-mediated disease |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20140357732A1 (enExample) |
| EP (1) | EP2704800B1 (enExample) |
| JP (1) | JP2014513958A (enExample) |
| KR (1) | KR20140074258A (enExample) |
| CN (1) | CN103874526A (enExample) |
| AU (1) | AU2012249521A1 (enExample) |
| BR (1) | BR112013027851A2 (enExample) |
| CA (1) | CA2834676A1 (enExample) |
| DK (1) | DK2704800T3 (enExample) |
| SG (1) | SG194235A1 (enExample) |
| WO (1) | WO2012149329A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| JP6829878B2 (ja) * | 2017-03-10 | 2021-02-17 | 国立大学法人浜松医科大学 | 加齢黄斑変性の発症リスクの評価方法 |
| EP3824095A4 (en) | 2018-07-20 | 2022-04-20 | University of Utah Research Foundation | GENE THERAPY FOR MACULATE GENERATION |
| KR102333953B1 (ko) * | 2020-07-10 | 2021-12-02 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 유전자 마커 |
| CN119694384B (zh) * | 2024-12-03 | 2025-10-03 | 南京医科大学 | 基于汇总统计数据的复杂性状关联基因检测方法及系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2357257B1 (en) * | 2005-02-14 | 2019-07-31 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| CA2599080A1 (en) * | 2005-03-04 | 2006-09-14 | Duke University | Genetic variants increase the risk of age-related macular degeneration |
| NZ574046A (en) * | 2006-07-13 | 2012-09-28 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| CA2704809A1 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Rca locus analysis to assess susceptibility to amd and mpgnii |
| US8114592B2 (en) * | 2008-03-18 | 2012-02-14 | Cambridge Enterprise Limited | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof |
| US20120115925A1 (en) * | 2008-12-23 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Allelic Variants Associated with Advanced Age-Related Macular Degeneration |
| WO2012051462A2 (en) * | 2010-10-14 | 2012-04-19 | Sequenom, Inc. | Complement factor h copy number variants found in the rca locus |
| WO2012082912A2 (en) * | 2010-12-14 | 2012-06-21 | Tufts Medical Center, Inc. | Markers related to age-related macular degeneration and uses therefor |
| JP2014515012A (ja) * | 2011-03-15 | 2014-06-26 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | 血管関連黄斑症およびその症状の診断および治療方法 |
| WO2014043558A1 (en) * | 2012-09-14 | 2014-03-20 | University Of Utah Research Foundation | Methods of predicting the development of amd based on chromosome 1 and chromosome 10 |
| US9896728B2 (en) * | 2013-01-29 | 2018-02-20 | Arcticrx Ltd. | Method for determining a therapeutic approach for the treatment of age-related macular degeneration (AMD) |
-
2012
- 2012-04-27 CN CN201280031235.6A patent/CN103874526A/zh active Pending
- 2012-04-27 US US14/114,751 patent/US20140357732A1/en not_active Abandoned
- 2012-04-27 KR KR1020137031638A patent/KR20140074258A/ko not_active Withdrawn
- 2012-04-27 JP JP2014508602A patent/JP2014513958A/ja active Pending
- 2012-04-27 DK DK12776262.3T patent/DK2704800T3/en active
- 2012-04-27 WO PCT/US2012/035467 patent/WO2012149329A2/en not_active Ceased
- 2012-04-27 BR BR112013027851A patent/BR112013027851A2/pt not_active IP Right Cessation
- 2012-04-27 AU AU2012249521A patent/AU2012249521A1/en not_active Abandoned
- 2012-04-27 EP EP12776262.3A patent/EP2704800B1/en active Active
- 2012-04-27 SG SG2013080502A patent/SG194235A1/en unknown
- 2012-04-27 CA CA2834676A patent/CA2834676A1/en not_active Abandoned
-
2017
- 2017-06-27 US US15/634,892 patent/US20180155788A1/en not_active Abandoned
-
2020
- 2020-01-03 US US16/734,168 patent/US20200239958A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012149329A2 (en) | 2012-11-01 |
| EP2704800A4 (en) | 2015-04-29 |
| EP2704800B1 (en) | 2018-09-12 |
| CA2834676A1 (en) | 2012-11-01 |
| WO2012149329A3 (en) | 2012-12-20 |
| US20140357732A1 (en) | 2014-12-04 |
| JP2014513958A (ja) | 2014-06-19 |
| CN103874526A (zh) | 2014-06-18 |
| EP2704800A2 (en) | 2014-03-12 |
| US20180155788A1 (en) | 2018-06-07 |
| DK2704800T3 (en) | 2019-01-14 |
| US20200239958A1 (en) | 2020-07-30 |
| KR20140074258A (ko) | 2014-06-17 |
| BR112013027851A2 (pt) | 2017-11-07 |
| AU2012249521A1 (en) | 2013-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502292A1 (en) | Methods and compositions for treatment of a genetic condition | |
| MX355543B (es) | Macrociclos peptidomiméticos. | |
| PH12014501844A1 (en) | Peptidomimetic macrocycles | |
| MX2014006130A (es) | Metodos de diagnostico y tratamiento de la fibrosis pulmonar idiopatica. | |
| UA107827C2 (xx) | Антитіло до cd40 | |
| IN2014DN11201A (enExample) | ||
| HK1199290A1 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| WO2012173846A3 (en) | Peptidomimetic macrocycles | |
| JO3755B1 (ar) | تركيبات تستوستيرون | |
| ZA201205432B (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO2012166626A8 (en) | Reagents and methods for treating dental disease | |
| EP2675478A4 (en) | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP | |
| MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
| PL2718434T3 (pl) | Kompozycje i sposoby leczenia choroby trzewnej | |
| PL2575968T3 (pl) | Związki do leczenia chorób powiązanych z clostridium difficile | |
| IN2014DN00254A (enExample) | ||
| SG194235A1 (en) | Methods of predicting the development of complement-mediated disease | |
| MX363385B (es) | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. | |
| UY34286A (es) | Diagnóstico de vacuna mejorado | |
| IN2015DN02818A (enExample) | ||
| GB201013060D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
| GB201009091D0 (en) | Compounds for the treatment of clostridium difficile-associated disease | |
| MX352296B (es) | Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades. | |
| MX2012012509A (es) | Tapentadol para usarse en el tratamiento del sindrome del intestino irritable. | |
| GB201013058D0 (en) | Compounds for the treatment of clostridium difficile associated disease |